EPO Extends Xarelto’s (Rivaroxaban) Patent Expiration Until Jan. 2026 – Myhealthyclick.com

Bayer announced Friday that the European Patent Office has extended the patent expiration of the company’s drug Xarelto (rivaroxaban) until January 2026, not allowing generics to enter the market until that deadline. Xarelto is the best-selling...